How do you decide on long-term nucleos(t)ide therapy vs intensified MASLD management/monitoring in an HBeAg-negative indeterminate-phase patient with mildly elevated/fluctuating ALT, low-level HBV DNA, and borderline VCTE stiffness (around 8 kPa) where MASLD may confound fibrosis assessment?